Brief: Ribomic says substance patent assessment for anti-midkine aptamers in US
31/08/2016 07:29
Aug 31 (Reuters) - Ribomic Inc 4591.T :
* Says co receives substance patent assessment for
anti-midkine aptamers, which is jointly developed with Otsuka
Pharmaceutical Co., Ltd., in US
Source text in Japanese: https://goo.gl/7aRvv6
Further company coverage: 4591.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 62674724;
Reuters Messaging: Cheng.Li@thomsonreuters.com@reuters.net))